IL-29/IFN-lambda 1 Antibody

Recombinant Human IL‑29/IFN‑ lambda 1 (Catalog # 1598-IL) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepato­cellular carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Human IL‑29/IFN‑ lambda 1 (40 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL‑29/IFN‑ lambda 1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1598). The ND50 is typically 0.2-1.0 µg/mL.

• Reactivity: Hu
• Applications: WB, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

IL-29/IFN-lambda 1 Antibody Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human IL-29/IFN-lambda 1
  Gly20-Thr200
  Accession # Q8IU54
• Specificity: Detects human IL-29/IFN-lambda 1 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 25% cross-reactivity with recombinant human (rh) IL‑28A and rhIL-28B is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: IFNL1
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 0.2-1.0 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-29/IFN-lambda 1 Antibody

• cytokine Zcyto21
• IFNL1
• IFN-lambda 1
• IFN-lambda-1
• IL29
• IL-29
• interferon lambda-1
• interferon, lambda 1
• interleukin 29 (interferon, lambda 1)
• interleukin-29
• ZCYTO21

Background

IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13% aa sequence identity) and the type I IFN family (15-19% aa sequence identity) (1-3). The genes encoding these three cytokines are localized to chromosome 19 and each is composed of multiple exons. The exon organization of these genes is also found in the IL-10 family genes but is distinct from the type I IFNs, which are encoded within a single exon, The expression of IL-28A, B, and IL‑29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor  beta (IL-10 R beta ) and a novel IL-28 receptor  alpha (IL-28 R alpha , also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN-regulatory factor 9 (IRF-9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory region of the target genes. Human IL-29 cDNA encodes a 200 amino acid (aa) residue precursor protein with a putative 19 aa signal peptide and a 181 aa mature protein, which is a monomer in solution. It shares 67% and 69% aa sequence identity with human IL-28A and IL-28B, respectively.

1. Vilcek, J. (2003) Nature Immunol. 4:8.
2. Sheppard, P. et al. (2003) Nature Immunol. 4:63.
3. Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-29/IFN-lambda 1 Antibody (AF1598)(12)

Publications using AF1598

• Chen, P;Wang, K;Lin, M;Sharma, R;Kalajzi?, Ž;O’Brien, M;Yadav, S; Alendronate partially rescues the periodontal defects in OIM mouse model of osteogenesis imperfecta Scientific reports 2025-01-02 [PMID: 39747677] (Immunohistochemistry, Mouse)
• M Tsai, W Osman, J Adair, R ElMergawy, L Chafin, F Johns, D Farkas, A Elhance, J Londino, RK Mallampall The E3 ligase subunit FBXO45 binds the interferon-lambda receptor and promotes its degradation during influenza virus infection The Journal of Biological Chemistry, 2022-11-13;0(0):102698. 2022-11-13 [PMID: 36379255] (Neutralization, Human)
• G Gallo, P Kotlik, P Roingeard, M Monot, G Chevreux, RG Ulrich, N Tordo, M Ermonval Diverse susceptibilities and responses of human and rodent cells to orthohantavirus infection reveal different levels of cellular restriction PloS Neglected Tropical Diseases, 2022-10-12;16(10):e0010844. 2022-10-12 [PMID: 36223391] (Neutralization, Mouse)
• The Effect of Chronic Hepatitis B Virus Infection on BDCA3+ Dendritic Cell Frequency and Function PLoS ONE, 2016-08-16;11(8):e0161235. 2016-08-16 [PMID: 27529176] (Bioassay, Human)
• Replication of human norovirus RNA in mammalian cells reveals a lack of interferon response J Virol, 2016-09-12;0(0):. 9/12/2016 [PMID: 27466422]
• Kirsten C. Eberle, Jodi L. McGill, Timothy A. Reinhardt, Randy E. Sacco Parainfluenza Virus 3 Blocks Antiviral Mediators Downstream of the Interferon Lambda Receptor by Modulating Stat1 Phosphorylation Journal of Virology 2016-03-15 [PMID: 26719274]
• Popugaeva E, Witkowski PT, Schlegel M, Ulrich RG, Auste B, Rang A, Kruger DH, Klempa B Dobrava-Belgrade hantavirus from Germany shows receptor usage and innate immunity induction consistent with the pathogenicity of the virus in humans. PLoS ONE, 2012-04-24;7(4):e35587. 2012-04-24 [PMID: 22545121] (Neutralization, Human)
• Boris Klempa, Peter T. Witkowski, Elena Popugaeva, Brita Auste, Lamine Koivogui, Elisabeth Fichet-Calvet et al. Sangassou Virus, the First Hantavirus Isolate from Africa, Displays Genetic and Functional Properties Distinct from Those of Other Murinae-Associated Hantaviruses Journal of Virology 2012-04-01 [PMID: 22278233]
• Li Q, Kawamura K, Okamoto S, Fujie H, Numasaki M, Namba M, Nagata M, Shimada H, Kobayashi H, Tagawa M Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-lambda genes produced anti-tumour effects. Br. J. Cancer, 2011-09-27;105(9):1302-12. 2011-09-27 [PMID: 21952623] (Western Blot, Human)
• Joseph Prescott, Pamela Hall, Mariana Acuna-Retamar, Chunyan Ye, Marc G. Wathelet, Hideki Ebihara et al. New World hantaviruses activate IFNlambda production in type I IFN-deficient vero E6 cells PLoS ONE 2010-06-17 [PMID: 20567522]
• Khaitov MR, Laza-Stanca V, Edwards MR, Walton RP, Rohde G, Contoli M, Papi A, Stanciu LA, Kotenko SV, Johnston SL Respiratory virus induction of alpha-, beta- and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cells. Allergy, 2009-01-28;64(3):375-86. 2009-01-28 [PMID: 19175599] (ELISA Development, Human)
• Yang K, Puel A, Zhang S, Eidenschenk C, Ku CL, Casrouge A, Picard C, von Bernuth H, Senechal B, Plancoulaine S, Al-Hajjar S, Al-Ghonaium A, Marodi L, Davidson D, Speert D, Roifman C, Garty BZ, Ozinsky A, Barrat FJ, Coffman RL, Miller RL, Li X, Lebon P, Rodriguez-Gallego C, Chapel H, Geissmann F, Jouanguy E, Casanova JL Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity, 2005-11-01;23(5):465-78. 2005-11-01 [PMID: 16286015] (ELISA Development, Human)

Bioinformatics

• Gene Symbol: IFNL1
• Uniprot:
  • Q8IU54()